National Kidney Foundation Spring 2018 Clinical Meetings

National Kidney Foundation Spring 2018 Clinical Meetings

Patients May Only Partially Report Symptom Burden of Hemodialysis

Austin, Texas—Patients on maintenance dialysis experience substantial burden of symptoms that are associated with impaired quality of life. Symptom control is cited as a top research priority by patients, but results of previous studies suggest that providers may underestimate the burden on patients. Researchers at the University of North Carolina, Chapel Hill, led by Adeline Dorough, BS, conducted a qualitative ... Read More »

Tolvaptan Reduced Renal-Pain Associated Costs in ADPKD Patients

Austin, Texas—Autosomal dominant polycystic kidney disease (ADPKD) is a progressive genetic kidney disease characterized by enlargement of bilateral renal cysts leading to loss of renal function. The TEMPO 3:4 trial demonstrated the efficacy of tolvaptan, a selective vasopressin V2-receptor antagonist. TEMPO 3:4 was a randomized, placebo-controlled trial involving 1445 patients over 3 years. An analysis of prespecified end points showed ... Read More »

Uromodulin Associated with Reduced Risk for Graft Failure

Austin, Texas—Andrew Bostom, MD, of the Center for Primary Care and Prevention, Memorial Hospital of Rhode Island, Pawtucket, recently conducted an analysis of longitudinal follow-up data from a study of 91 recipients of kidney transplantation. The analysis was designed to examine the association between baseline serum uromodulin and the development of graft failure. Uromodulin is a kidney-derived glycoprotein and putative ... Read More »

Vascapa® Reduces Triglycerides in Patients with Reduced Kidney Function and Elevated hsCRP

Austin, Texas—Patients with kidney disease and elevated high-sensitivity C-reactive protein (hsCRP) are at increased risk for cardiovascular disease. Vascepa® (icosapent ethyl), a high-purity ethyl ester of the omega-3 fatty acid, eicosapentaenoic acid, is approved at 4 g per day as an adjunct to diet to reduce triglycerides in adults with triglyceride level ≥500 mg/dL. Krishnaswami Vijsyaraghavan, MD, and colleagues conducted ... Read More »

Patiromer Shown Safe and Effective in Three Clinical Trials in Patients with Hyperkalemia

Austin, Texas—Veltassa® (patiromer), a sodium free, nonbasorbed potassium binder, is approved for treatment of patients in the United States and the European Union with hyperkalemia. Matthew Weir, MD, and colleagues recently conducted an analysis to examine the consistency of lowering serum potassium in trials of patiromer for hyperkalemia. Results of the analysis were reported during a poster session at the ... Read More »

Canagliflozin Safe and Effective in Patients with Reduced and Preserved Kidney Function

Austin, Texas—Glucose lowering in patients with type 2 diabetes can be achieved with sodium glucose co-transporter 2 inhibitors; the agents may confer renal benefits but because the glycemic efficacy is dependent on glomerular filtration rate (GFR), they are not approved for use in people with significantly reduced kidney function. Researchers recently performed a prespecified analysis of CANVAS (Canagliflozin Cardiovascular Assessment ... Read More »

Volume Overload Kidney Transplant Recipients Require More Treatments than Those with Hyperkalemia

Austin, Texas—In up to 60% of kidney transplantations with deceased donors and 8% with living donors, delayed graft function or dialysis occurs within 7 days following the procedure. Jacentha Buggs, MD, and colleagues conducted a retrospective cohort study to test the hypothesis that that is a difference in resource utilization based on the indication for dialysis in delayed graft function. ... Read More »